Most Read This Week
- Ribociclib Plus Endocrine Therapy After Progression on Anti-Estrogen Therapy Plus CDK 4/6 Inhibition in Patients With Unresectable HR+/HER2− MBC
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- ASCO 2022: MAINTAIN Demonstrates Role for Ribociclib Following Progression of HR-Positive/HER2-Negative Metastatic Breast Cancer on a CDK4/6 Inhibitor
- ASCO 2022: Trastuzumab Deruxtecan Bests Standard-of-Care Chemotherapy in HER2-Low Metastatic Breast Cancer
- Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Patients With HER2+ Unresectable and/or Metastatic Breast Cancer
Recently Updated
- Oligometastatic Germline BRCA-Mutant Triple-Negative Breast Cancer With Metastasectomy — Further Treatment Options?
- Fulvestrant Plus Capivasertib vs Placebo After Relapse or Progression on an Aromatase Inhibitor in Patients With ER+, HER2− MBC
- Overall Survival With First-Line Palbociclib Plus Letrozole vs Placebo Plus Letrozole in Women With ER+/HER2− Advanced Breast Cancer
- Standard of Care Systemic Therapy With or Without SBRT and/or Surgical Resection for Oligometastatic Breast Cancer
- Patritumab Deruxtecan in Patients With HER3-Expressing MBC